Encephalopathy is a disease that affects the structure and functioning of the brain, which can be permanent or temporary. The different types of encephalopathy include chronic traumatic encephalopathy, glycine encephalopathy, Hashimoto’s encephalopathy, hepatic encephalopathy, hypertensive encephalopathy, hypoxic ischemic encephalopathy, toxic-metabolic encephalopathy, infectious encephalopathies, uremic encephalopathy and Wernicke encephalopathy. Some of the symptoms associated with the disease inclcude mental changes, muscle weakness, trembling, involuntary twitching, difficulty speaking or swallowing and seizures. The disease can be prevented by avoiding excess alcohol, eating a healthy diet and reducing exposure to toxic substances such as drugs. Rebiotix Inc. is in the process of developing RBX2660 for the treatment of hepatic encephalopathy as an enema formulation. Some of the other companies having a pipeline of encephalopathy include Greenwich Biosciences, Inc., and GW Pharmaceuticals, plc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.